{
    "ticker": "ADPT",
    "name": "Adaptive Biotechnologies Corporation",
    "description": "Adaptive Biotechnologies Corporation is a biotechnology company that focuses on the development of innovative immune-driven medicine solutions. Founded in 2009 and headquartered in Seattle, Washington, Adaptive leverages its proprietary immune profiling technology to transform the understanding and treatment of diseases, particularly in oncology and autoimmune disorders. The company\u2019s flagship products include the clonoSEQ assay, which is designed to detect and monitor minimal residual disease in patients with blood cancers, and the immunoSEQ platform, which provides comprehensive immune profiling data to researchers and clinicians. By enabling the development of personalized therapies, Adaptive aims to improve patient outcomes and advance the field of precision medicine. The company collaborates with leading pharmaceutical and biotechnology companies to develop therapies that harness the power of the immune system. As an industry leader in immune sequencing and data analytics, Adaptive is committed to advancing scientific research and providing valuable insights into the human immune system, ultimately striving to fulfill its mission of making immune-driven medicines a reality for all.",
    "industry": [
        "Biotechnology",
        "Healthcare"
    ],
    "headquarters": "Seattle, Washington, USA",
    "founded": "2009",
    "website": "https://www.adaptivebiotech.com",
    "ceo": "Chad Robins",
    "social_media": {
        "twitter": "https://twitter.com/adaptivebiotech",
        "linkedin": "https://www.linkedin.com/company/adaptivebiotechnologies/"
    },
    "investor_relations": "https://investors.adaptivebiotech.com",
    "key_executives": [
        {
            "name": "Chad Robins",
            "position": "CEO"
        },
        {
            "name": "Darryl Sampey",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Diagnostic Assays",
            "products": [
                "clonoSEQ",
                "immunoSEQ"
            ]
        },
        {
            "category": "Therapeutic Development",
            "products": [
                "Immune-driven therapies"
            ]
        }
    ],
    "seo": {
        "meta_title": "Adaptive Biotechnologies | Immune-driven Medicine Solutions",
        "meta_description": "Discover Adaptive Biotechnologies, a leader in immune-driven medicine. Explore innovative diagnostic assays and therapeutic development aimed at advancing precision medicine.",
        "keywords": [
            "Adaptive Biotechnologies",
            "Biotechnology",
            "Immune Profiling",
            "Cancer Diagnostics",
            "Precision Medicine",
            "clonoSEQ",
            "immunoSEQ"
        ]
    },
    "faq": [
        {
            "question": "What does Adaptive Biotechnologies specialize in?",
            "answer": "Adaptive Biotechnologies specializes in immune-driven medicine and develops innovative diagnostic assays and therapies based on immune profiling."
        },
        {
            "question": "What are some of Adaptive's key products?",
            "answer": "Adaptive's key products include the clonoSEQ assay for blood cancer monitoring and the immunoSEQ platform for immune profiling."
        },
        {
            "question": "When was Adaptive Biotechnologies founded?",
            "answer": "Adaptive Biotechnologies was founded in 2009."
        },
        {
            "question": "Where is Adaptive Biotechnologies headquartered?",
            "answer": "Adaptive Biotechnologies is headquartered in Seattle, Washington, USA."
        }
    ],
    "competitors": [
        "NVTA",
        "EXAS",
        "TMO",
        "RHHBY"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "CELG"
    ]
}